Migraine,Serotonin and Sumatriptan

Olesen J Edvinsson L. Migraine: A research field matured for the basic neurosciences. Trends Neurosci 1991; 14: 3–5.

Blau JN . The clinical diagnosis of migraine: The beginning of therapy. J Neurol 1991; 238 (suppl 1): S6–11.

Moskowitz MA . Neurobiology of vascular head pain. Ann Neurol 1984; 16: 157–68.

Moskowitz MA Buzzi MG Sakas DE Linnik MD . Pain mechanisms underlying vascular headaches. Rev Neurol (Paris) 1989; 145: 181–93.

Humphrey PPA Feniuk W Perren MJ . GR43175, a selective agonist for the 5-HT,-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988; 94: 1123–32.

Humphrey PPA Feniuk W Perren MJ Connor HE Oxford AW . The pharmacology of the novel 5-HT₁-like receptor agonist, GR43175. Cephalalgia 1989; 9 (suppl 9): 23–33.

Ferrari MD and the Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316–21.

Cady RK Wendt JL Kirchner JR Sargent JD Rothrock JF Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–35.

The Oral Sumatriptan Dose-Defining Study Group (Greenford). Sumatriptan — an oral dose-defining study. Eur Neurol 1991; 31: 300–305.

World Federation of Neurology, Research Group on Migraine and Headache. Definition of migraine. In: Cochrane AL ed. Background to migraine. New York: Heineman, 1970: 181–82.

Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 7 (suppl 8): 1–96.

Graham JR Wolff HG . Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938; 39: 737–63.

Wolff HG . Headache and other head pain. New York: Oxford Univesity Press, 1963.

Humphrey PPA . 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991; 238 (suppl 1): S38–44.

Raskin NH . Pharmacology of migraine. Annu Rev Pharmacol Toxicol 1981; 21: 463–78.

Olesen J Larsen B Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981; 9: 344–52.

Friberg L. Cerebral blood flow changes in migraine: Methods, observations and hypotheses. J Neurol 1991; 238 (suppl 1): S12–17.

Leao AAP . Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 359–90.

Olsen Skyhøj T Friberg L Lassen NA . Ischaemia may be the primary cause of the neurological deficits in classic migraine. Arch Neurol 1987; 44: 156–61.

Olesen J Tfelt-Hansen P Henriksen L Larsen B. The common migraine attack may not be initiated by cerebral ischaemia. Lancet 1981; ii: 438–40.

Ray BS Wolff HG . Experimental studies on headache: Pain sensitive structures of the head and their significance in headache. Arch Surg 1940; 41: 813–56.

Nichols FT Mawad M Mohr JP Stein B Hilal S Michelsen WJ . Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 1990; 21: 555–59.

Edvinsson L McCulloch J Uddman R. Substance P: Immunohistochemical localisation and effect upon cat pial arteries in vitro and in situ. J Physiol (Lond) 1981; 318: 251–58.

Friberg L Olesen J Iverson HK Sperling B. Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan. Lancet 1991; 338: 13–17.

Moskowitz MA . The anatomy and neurochemistry of trigeminovascular neurons. In: Owman C Hardebo JE eds. Neural regulation of brain circulation. Amsterdam: Elsevier, 1986: 393–405.

Lance JW . A concept of migraine and the search for the ideal headache drug. Headache 1990; 30 (suppl 1): 17–23.

Zagami AS Goadsby PJ Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990; 16: 69–75.

Geppetti P Bianco ED Santicioli P Lippe ITH Maggi CA Sicuteri F. Release of sensory neuropeptides from dural venous sinuses of guinea-pig. Brain Res 1990; 510: 58–62.

Jansen I Alafaci C McCulloch J Uddman R Edvinsson L. Tachykinins (substance P, neurokinin A, neuropeptide K and neurokinin B) in the cerebral circulation: Vasomotor responses in vitro and in situ. J Cereb Blood Flow Metab 1991; 11: 567–75.

McCulloch J Uddman R Kingman TA Edvinsson L. Calcitonin gene-related peptide: Functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986; 83: 5731–35.

Brain SD Williams TJ . Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. B J Pharmacol 1985; 86: 855–60.

Buzzi MG Moskowitz MA . The antimigraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br Pharmacol 1990; 99: 202–206.

Goadsby PJ Edvinsson L Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183–87.

Sicuteri F Testi A Anselmi B. Biochemical investigation in headache: Increase in the hydroxyindolacetic acid excretion during migraine attacks. Int Arch Allergy Appl Immunol 1961; 19: 55–58.

Curran DA Hinterberger H Lance JW . Total plasma serotonin, 5-hydroxyindolacetic acid and β-hydroxy-mmethoxymandelic acid excretion in normal and migrainous subjects. Brain 1965; 88: 997–1007.

Anthony M Hinterberger H Lance JW . Plasma serotonin in migraine and stress. Arch Neurol 1967; 16: 544–52.

Kimball RW Friedman AP Valeejo E. Effect of serotonin in migraine patients. Neurology 1960; 10: 107–11.

Bonvento G Lancombe P MacKenzie ET Rouquier L Scatton P Seylaz J. Differential effects of electrical stimulation of the dorsal raphe nucleus and of cervical sympathectomy on serotonin and noradrenaline concentrations in major cerebral arteries and pial vessels in the rat. J Cereb Blood Flow Metab 1990; 10: 123–26.

Hoyer D. 5-Hydroxytryptamine receptors and effector mechanisms in peripheral tissue. In: Fozard JR ed. The peripheral actions of 5-hydroxytryptamine. New York: Oxford University Press, 1989: 72–99.

Brown AM Patch TL Kaumann AJ . The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT_1c receptor agonists in piglet choroid plexus. Br J Pharmacol 1991; 104: 45–48.

Humphrey PPA Feniuk W Perren MJ Beresford IJM Skingle M. Serotonin and migraine. Ann NY Sci 1990; 600: 587–600.

Humphrey PPA Feniuk W Motevalian M Parsons AA Whalley ET . The vasoconstrictor action of sumatriptan on human isolated perfused dura mater. In: Fozard JR Saxena PR eds. Serotonin: Molecular biology, receptors and functional effects. Basel: Birkhäuser Verlag, 1991: 421–29.

Parsons AA Whalley ET Feniuk W Connor HE Humphrey PPA . 5-HT₁-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol 1989; 96: 434–49.

McCarthy BG Peroutka SJ . Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR43175). Headache 1989; 29: 420–22.

Van Wijngaarden I Tulp MThM Soudijn W. The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 1990; 188: 301–12.

Humphrey PPA Apperley E Feniuk W Perren MJ . A rationale approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR Wallis DI Wouters W Bevan P eds. Cardiovascular pharmacology of 5-hydroxytryptamine. Dordrecht: Kluwer, 1990: 417–31.

Cohen ML . 5-hydroxytryptamine and non-vascular smooth muscle contraction and relaxation. In: Fozard JR ed. The peripheral actions of 5-hydroxytryptarnine. Oxford: Oxford Medical Publications, 1989: 201–19.

Clarke DE Baxter GS Young H Craig DA . Pharmacological properties of the putative 5-HT⁴ receptor in guinea-pig ileum and rat oesophagus: Role in peristalsis. In: Fozard JR Saxena PR eds. Serotonin: Molecular biology, receptors and functional effects. Basel: Birkhäuser Verlag, 1991: 232–42.

The Sumatriptan Autoinjector Study Group (Greenford). Self treatment of acute migraine with subcutaneous sumatriptan using an autoinjector device. Eur Neurol 1991; 31: 323–31.

The Oral Sumatriptan International Multiple-Dose Study Group (Greenford). Evaluation of a multiple dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306–13.

Tansey MJB Pilgrim AJ Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1992 (in press).

Skingle M Birch PJ Leighton GE Humphrey PPA . Lack of antinociceptive activity of sumatriptan in rodents. Cephalalgia 1990; 10: 207–12.

Humphrey PPA Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444–46.

Perren MJ Feniuk W Humphrey PPA . The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 1989; 9 (suppl 9): 41–46.

Connor HE Stubbs CM Feniuk W Humphrey PPA . Effect of sumatriptan, a selective 5-HT₁-like receptor agonist, on pial vessel diameter in anaesthetised cats. J Cereb Blood Flow Metab 1992; 12: 514–19.

Knudsen GM Juhler M Paulson OB . Morphology, physiology and pathophysiology of the blood brain barrier. In: Olesen J Edvinsson L eds. Basic mechanisms of headache. Amsterdam: Elsevier, 1988p: 49–60.

Caekebeke JFV Ferrari MD Zwetsloot CP Jansen I Saxena PR . The antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992 (in press).

Goadsby PJ Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991; 11: (suppl 11): 3–4.

Ekbom K and the Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991; 325: 322–26.

Müller-Schweinitzer E. Vascular effects of ergot alkaloids: A study on human basilar artery. Gen Pharmacol 1983; 14: 95–102.

Den Boer MO Villalón CM Heiligers PCJ Humphrey PPA Saxena PR . Role of 5-HT₁-like receptors in the reduction of porcine arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102: 323–30.

Den Boer MO Heiligers JPC Saxena PR . Carotid vascular effects of ergotamine and dihydroergotamine in the pig: No exclusive mediation via 5-HT₁-like receptors. Br J Pharmacol 1991; 104: 183–89.

Ziegler A. Treatment: Where are we going? In: Sandler M Collins G eds. Migraine: A spectrum of ideas. New York: Oxford University Press, 1990: 294–300.

Eckert H Kiechel JR Rosenthaler J Schmidt R Schreier E. Biochemical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In: Berde B Schild HO eds. Ergot alkaloids and related compounds. Berlin: Springer-Verlag, 1978: 719–803.

Ala-Hurula V Myllylä VV Kärki NT Hokkanen E. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol 1979; 16: 355–60.

Sanders SW Haering N Mosberg H Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1986; 30: 331–34.

Goadsby PJ Gundlach AL . Localisation of ³H-dihydroergotamine binding sites in the cat central nervous system: Relevance to migraine. Ann Neurol 1991; 29: 91–94.

The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomised, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314–22.

Bradfield JM . A new look at the use of ergotamine. Drugs 1976; 12: 449–53.

Tfelt-Hansen P Kanstrup IL Christensen NJ Winkler K. General and regional haemodynamic effects of intravenous ergotamine. Clin Sci 1983; 65: 599–604.

Richardson BP Engel G Bucheit K-H . Defective serotonergic neurotransmission: A possible cause of migraine and a basis for the efficacy of ergot compounds in the treatment of attacks. In: Lance JW ed. Recent trends in the management of migraine. Bad Buchau: Vereinigte Buchdruckerein, 1987: 9–21.

Muller-Schweinitzer E Sturmer E. Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Br J Pharmacol 1974; 51: 441–46.

Saxena PR Cairo-Rawlins WI . Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulation in the cat. Eur J Pharmacol 1979; 58: 305–12.

Bodia A Moron A Cuffi L Vila E. Effects of ergotamine on cardiovascular catecholamine receptors in the pithed rat. Gen Pharmacol 1988; 19: 475–81.

Feniuk W Humphrey PPA Perren MJ . GR43175 does not share the complex pharmacology of the ergots. Cephalalgia 1989; 9 (suppl 9): 35–39.

Fozard JR Gray JA . 5-HT_1c-receptor activation: A key step in the initiation of migraine. Trends Pharmacol Sci 1989; 10: 307–309.

Brewerton TD Murphy DL Mueller EA Jimerson DC . Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988; 43: 605–609.

Andersson PG . Ergotamine headache. Headache 1975; 15: 118–21.

Saper JR Jones MJ . Ergotamine tartrate dependency: Features and possible mechanisms. Clin Neuropharmacol 1986; 9: 244–56.

Wilkinson M Orton S. Some observations on the use of ergotamine tartrate. Headache 1980; 20: 159.

Brown EG Endersby CA Smith RN Talbot JCC . The safety and tolerability of sumatriptan: An overview. Eur Neurol 1991; 31: 339–44.

Tansey MJB . Sumatriptan long term data and future developments. Abstract presented at International Headache Society, Washington, 1991.